関連する実験動画
Updated: Jan 9, 2026
01:27
Pulmonary Embolism III: Nursing Management
Published on: June 19, 2025
320
miR-181aは,T細胞の感受性と選択の固有の調節剤です
Qi-Jing Li1, Jacqueline Chau, Peter J R Ebert
1Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cell
|March 27, 2007
まとめ
マイクロRNA-181a (miR-181a) は,発達の過程でT細胞の抗原に対する感受性を微調整するレオスタットとして作用する. その発現レベルは,T細胞の選択,免疫,および耐性を決定的に影響する.
科学分野:
- 免疫学 免疫学とは
- 分子生物学は分子生物学である.
- 発達生物学 発達生物学とは
背景:
- 抗原に対するT細胞の感受性は,免疫反応と自己耐性にとって極めて重要です.
- 成熟期中のT細胞の抗原感受性を調節する内在的なメカニズムは完全に理解されていません.
- マイクロRNA (miRNA) は,免疫細胞の発達に役割を果たす遺伝子発現のレギュレータとして知られています.
研究 の 目的:
- 抗原に対するT細胞感受性の調節におけるmicroRNA-181a (miR-181a) の役割を調査する.
- miR-181aがT細胞受容体シグナリングを調節する分子メカニズムを解明する.
- T細胞の発達,選択,および機能に対するmiR-181aの影響を決定する.
主な方法:
- 未成熟T細胞と成熟T細胞の両方の miR-181a発現の調節.
- アゴニストとアンタゴニストを含む様々なペプチド抗原に対するT細胞の感受性の評価.
- T細胞受容体のシグナル伝達経路の分析,フォスファターゼ活性とリン酸化レベルを含む.
- T細胞の陽性と陰性の選択過程の評価.
主要な成果:
- 成熟したT細胞におけるmiR-181a発現の増加は,抗原に対する感受性を高めます.
- 未成熟のT細胞におけるmiR-181aの抑制により,感受性が低下し,ポジティブ/ネガティブの選択が損なわれます.
- miR-181aは,フォスファタゼをダウンレギュレーションすることで,T細胞の感受性を調節し,シグナリング値を下げました.
- miR-181aは,アンタゴニストペプチドをアゴニストとして認識することを可能にしました.
結論:
- miR-181aは,発達中のT細胞の抗原感受性を制御する内在的なレオスタットとして機能します.
- miR-181aの定量調節は,適切なT細胞選択,免疫,および耐性のために不可欠です.
- miR-181aがフォスファターゼの活性を調節する役割は,T細胞受容体のシグナル伝達値に影響する.
関連する概念動画
Pulmonary Embolism III: Nursing Management
320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction
464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II
852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K